Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Goal To examine whether lipid lowering medications (LLMs) and especially statin drugs can delay cognitive decline and dementia onset in individuals with and without Mild Cognitive Impairment (MCI) at baseline. Methods Longitudinal, observational study of 3,069 cognitively healthy elderly, ages 75 years and older, who were enrolled in the Ginkgo Evaluation of Memory Study. Primary outcome measure was the time to adjudicated all-cause dementia and Alzheimer dementia (AD). Secondary outcome measure was the change in global cognitive function over time measured by 3MSE and ADAS-cog scores. Findings Among participants without MCI at baseline current use of statins was consistently associated with a reduced risk of all cause dementia (HR 0. 79, 95% confidence interval, 0.65–0.96, p=0.021) and AD (HR 0.57, 95% confidence interval, 0.39–0.85, p= 0.005). In participants who initiated statin therapy lipophilic statins tended to reduce dementia risk more than nonlipophilic agents. In contrast there was no significant association between LLM use (including statins), dementia onset or cognitive decline in individuals with baseline MCI. However, in individuals without MCI at baseline there was a trend for a neuroprotective effect of statins on cognitive decline. Conclusions Statins may slow the rate of cognitive decline and delay the onset of AD and all cause dementia in cognitively healthy elderly individuals whereas individuals with MCI may not have comparable cognitive protection from these agents. However, the results from this observational study need to be interpreted with caution and will require confirmation by randomized clinical trials stratifying treatment groups based on MCI status at baseline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · cited 1×
“The results of these randomized controlled studies seem to conflict with the finding that statins significantly reduce ischemic stroke risk.(19,20,22-26) Because randomized controlled trials of statins reduced the incidence of cerebral ischemic events by about 10% to 30%,(19,20,27) it is surprising that the same inter…”
ResultThe Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Lopez, O. L., Jagust, W. J., DeKosky, S. T., Becker, J. T., Fitzpatrick, A., Dulberg, C., Breitner, J., Lyketsos, C., Jones, B., Kawas, C., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.10.1385 · Cited by 618
Self-citationRandomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438 · cited 2×
“Prospective clinical trials did not show a protective effect of statins on cognition, but these studies were either not primarily designed to examine the effects of statin on cognitive function and enrolled predominantly participants with advanced vascular disease, including cerebrovascular disease,(19,20) or studied…”
ResultRelation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Reitz, C., Tang, M.-X., Luchsinger, J., & Mayeux, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.705 · Cited by 397 · cited 1×
“Controversy continues whether increased cholesterol levels are associatedwith an increased risk of AD and other dementias.(6-9)”
BackgroundHaag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 3×
“Some observational studies have suggested a lower rate of dementia in individuals receiving statins, but other studies yielded negative results.(10-18) Prospective clinical trials did not show a protective effect of statins on cognition, but these studies were either not primarily designed to examine the effects of st…”
ResultMechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235 · cited 2×
“It has been hypothesized that statins not only lower lipid levels and reduce atherosclerosis-related vascular disease, but that they also have multiple pleiotropic effects.(28-30,40)”
Background
Cited by
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Kueper, J. K., Speechley, M., & Montero-Odasso, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170991 · Cited by 424
Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease
Jia, L., Piña-Crespo, J., & Li, Y. (2019) · Molecular Brain · doi:10.1186/s13041-019-0525-5 · Cited by 288
Risk Factors for the Progression of Mild Cognitive Impairment to Dementia
Campbell, N. L., Unverzagt, F., LaMantia, M. A., Khan, B. A., & Boustani, M. A. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.009 · Cited by 288
Metadata
- Authors
- Bettermann, K., Arnold, A. M., Williamson, J., Rapp, S., Sink, K., Toole, J. F., Carlson, M. C., Yasar, S., DeKosky, S., & Burke, G. L.
- Venue
- Journal of Stroke and Cerebrovascular Diseases
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 21
- Issue
- 6
- Pages
- 436-444
- ISSN
- 1052-3057 (ISSN-L)
- OpenAlex
- W2142847995
- Cited by
- 132
- References
- 12
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study. https://app.cochat.ai/papers/10.1016/j.jstrokecerebrovasdis.2010.11.002
- The paper
- Bettermann, K., Arnold, A. M., Williamson, J., Rapp, S., Sink, K., Toole, J. F., Carlson, M. C., Yasar, S., DeKosky, S., & Burke, G. L. (2012). Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study. Journal of Stroke and Cerebrovascular Diseases. https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.11.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.